Department of Neurosurgery, University Hospital of Wales, Cardiff, UK.
Department of Pathology, University Hospital of Wales, Cardiff, UK.
Br J Neurosurg. 2020 Oct;34(5):584-586. doi: 10.1080/02688697.2019.1639616. Epub 2019 Jul 9.
A retrospective study over a three-year period at University Hospital of Wales (UHW) of the incidence of atypical cranial grade II meningioma both pre and post 2016 revision of The World Health Organisation (WHO) classification of tumours of the central nervous system. All available histology from January 2015 to December 2017 of patients with cranial meningiomas. Institutional online reporting system to identify patients and view histology reports. Overall 164 patient histology results were analysed (median age 59, age range 23-82, 74% females). There were 55 patients in 2015: 69.1% grade I, 29.1% grade II and 1.8% grade III. There were 109 patients in 2016/17; 68.8% grade I, 29.4% grade II, 1.8% grade III. There is significant variability in the reported incidence of grade II meningioma, likely due to variation in local interpretation of diagnostic criteria. Neuropathologists at our institution have reported brain invasion as grade II prior to 2016. This was due to compelling published evidence that brain invasive meningiomas have recurrence and mortality rates similar to that of grade II meningioma as defined using other criteria. The new 2016 WHO criteria now recognise this specifically. As other institutions adapt to the amended 2016 guidelines we anticipate that there will be a greater consensus in line with our incidence rates of grade II meningioma.
一项在威尔士大学医院(UHW)进行的为期三年的回顾性研究,调查了 2016 年世界卫生组织(WHO)中枢神经系统肿瘤分类修订前后,非典型颅部 II 级脑膜瘤的发病率。研究纳入了 2015 年 1 月至 2017 年 12 月期间所有颅部脑膜瘤患者的所有可用组织学资料。通过机构在线报告系统来识别患者并查看组织学报告。共分析了 164 例患者的组织学结果(中位年龄 59 岁,年龄范围 23-82 岁,女性占 74%)。2015 年有 55 例患者:69.1%为 I 级,29.1%为 II 级,1.8%为 III 级。2016/17 年有 109 例患者:68.8%为 I 级,29.4%为 II 级,1.8%为 III 级。脑膜瘤 II 级的报告发病率存在显著差异,这可能是由于当地对诊断标准的解释存在差异。我院神经病理学家在 2016 年之前曾将脑侵犯报告为 II 级。这是因为有强有力的证据表明,具有脑侵犯的脑膜瘤的复发率和死亡率与其他标准定义的 II 级脑膜瘤相似。新的 2016 年 WHO 标准特别承认了这一点。随着其他机构适应修订后的 2016 年指南,我们预计会有更多的共识,与我们的 II 级脑膜瘤发病率一致。